Active substance
Almotriptan malate
- US FDA 4
- US price lines 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALMOTRIPTAN MALATE | EQ 6.25MG BASE; EQ 12.5MG BASE | tablet · oral | TEVA PHARMS USA | Prescription | 7 Jul 2015 |
| ALMOTRIPTAN MALATE | EQ 6.25MG BASE; EQ 12.5MG BASE | tablet · oral | MYLAN | Prescription | 9 Nov 2015 |
| ALMOTRIPTAN MALATE | EQ 6.25MG BASE; EQ 12.5MG BASE | tablet · oral | AJANTA PHARMA LTD | Prescription | 3 Mar 2016 |
| AXERT | EQ 6.25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | JANSSEN PHARMS | Discontinued | 7 May 2001 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ALMOTRIPTAN MALATE 12.5 MG TAB | $16.85661 | per EA | 23 Sep 2026 |
| US NADAC | ALMOTRIPTAN MALATE 6.25 MG TAB | $16.50912 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 15 May 2017 AXERT — safety-related labeling change
Labeling sections changed: Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.